Credits Available: 4.75 AMA PRA Category 1 Credit™/ MOC Points

Description: This curriculum examines the latest advancements in antibody-drug conjugate (ADC) therapy for metastatic triple-negative breast cancer (mTNBC) and HER2-low (HER+/HER2-) breast cancer. It provides insights into mechanisms of action, emerging clinical data, and strategies for integrating ADCs into treatment regimens to improve patient outcomes. Expert-led discussions and case-based learning will support clinicians in individualizing therapy and addressing real-world challenges in ADC use.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse Practitioner, Physician Associate/Assistant
Target Specialties: Oncology

David Page

Providence Cancer Institute
Medical Oncology

I am a medical oncologist and clinical investigator in the field of breast cancer and immunology. I attended medical residency at the New York Presbyterian / Columbia University Medical Center, followed by fellowship at Memorial Sloan Kettering Cancer Center. Currently I practice at the Providence Cancer Institute in Portland, OR. In addition to seeing patients, I also conduct clinical trials evaluating novel immunotherapy combinations in breast cancer, and I investigate novel biomarkers strategies (such astumor infiltrating lymphocyte spatial analysis) to help guide clinical decision-making in the context of immunotherapy.